PSI met an interim enrollment milestone of 400 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV).
PSI completed the active treatment period in a phase II study of a novel biological agent in patients with asthma.
